Oramed Pharmaceuticals Inc.

Regulatory Filings • Feb 9, 2021

SEC Form 4
	FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION					Washington, D.C. 20549									OMB APPROVAL
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).		STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940										OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
1. Name and Address of Reporting Person* KIDRON NADAV					2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. [ ORMP ]								(Check all applicable) X Director X below)	Officer (give title	5. Relationship of Reporting Person(s) to Issuer X		10% Owner Other (specify
(Last) (First) (Middle) 1185 AVENUE OF THE AMERICAS					3. Date of Earliest Transaction (Month/Day/Year) 02/03/2021										below) President and CEO
(Street) NEW YORK NY 10036 (City) (State) (Zip)					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person
			Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) Date				2. Transaction (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)			3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following		(I) (Instr. 4)		6. Ownership Form: Direct (D) or Indirect	7. Nature of Indirect Beneficial Ownership
								Code V Amount		(D)	(A) or Price		Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)
			Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned					(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. 3. Transaction 3A. Deemed Conversion Date Execution Date, or Exercise (Month/Day/Year) if any Price of (Month/Day/Year) Derivative Security		4. 8)	Transaction Code (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			6. Date Exercisable and Expiration Date (Month/Day/Year)		of Securities Underlying (Instr. 3 and 4)	7. Title and Amount Derivative Security	8. Price of Derivative Security (Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code V	Amount or Date Expiration Number (A) (D) Exercisable Date Title of Shares			(Instr. 4)
Stock Option (right to buy)	\$10.4	02/03/2021		(1) A		150,000		(1)			02/03/2031 Common Stock	150,000	\$0		150,000		D

Explanation of Responses:

1. The Stock Option will vest in 4 equal installments as follows: 37,500 shall vest on each of December 31, 2021, December 31, 2022, December 31, 2023 and December 31, 2024.

/s/ Nadav Kidron 02/08/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

									or Section 30(h) of the Investment Company Act of 1940
1. Name and Address of Reporting Person* Kidron Miriam						2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. [								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
						ORMP ]									X Director			10% Owner
															X below)	Officer (give title		Other (specify below)
(Last)		(First)	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 02/03/2021
	2 ELZA STREET														Chief Scientific Officer
(Street)									4. If Amendment, Date of Original Filed (Month/Day/Year)					Line)				6. Individual or Joint/Group Filing (Check Applicable
JERUSALEM L3 93706														X Form filed by One Reporting Person
															Form filed by More than One Reporting
(City)		(State)	(Zip)												Person
			Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction						2A. Deemed Execution Date,			3. 4. Securities Acquired (A) or Transaction Disposed Of (D) (Instr. 3, 4 and 5)				5. Amount of Securities				6. Ownership Form: Direct	7. Nature of Indirect
Date				(Month/Day/Year)		if any (Month/Day/Year)		Code (Instr. 8)							Beneficially Owned Following		(D) or Indirect (I) (Instr. 4)	Beneficial Ownership
									Code V		Amount	(A) or (D)		Price	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)
			Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned						(e.g., puts, calls, warrants, options, convertible securities)
1. Title of	2.	3. Transaction	3A. Deemed		4.		5. Number of		6. Date Exercisable and				7. Title and Amount		8. Price of	9. Number of		10.	11. Nature
Derivative Security (Instr. 3)	Conversion or Exercise Price of Derivative Security	Date (Month/Day/Year)	Execution Date, if any (Month/Day/Year)	8)		Transaction Code (Instr.	Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expiration Date (Month/Day/Year)			of Securities Underlying Derivative Security (Instr. 3 and 4)			Derivative Security (Instr. 5)	derivative Securities Beneficially Owned Following Reported Transaction(s)		Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	of Indirect Beneficial Ownership (Instr. 4)
				Code V		(A)	(D)	Date Exercisable		Expiration Date	Title	Amount or Number of Shares			(Instr. 4)
Stock Option (right to buy)	\$10.4	02/03/2021			(1) A		100,000		(1)		02/03/2031 Common	Stock	100,000		\$0	100,000		D

Explanation of Responses:

1. The Stock Option will vest in 4 equal installments as follows: 25,000 shall vest on each of December 31, 2021, December 31, 2022, December 31, 2023 and December 31, 2024.

/s/ Miriam Kidron 02/08/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

SEC Form 4
------------	--

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).						STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
1. Name and Address of Reporting Person* Hexter Joshua						2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. [ ORMP ] X										(Check all applicable) Director Officer (give title	5. Relationship of Reporting Person(s) to Issuer 10% Owner Other (specify below)
(Last) 9 ALFASI ST.		(First)	(Middle) 3. Date of Earliest Transaction (Month/Day/Year) 02/03/2021										below)		COO, Business Officer
(Street) JERUSALEM L3 92302						4. If Amendment, Date of Original Filed (Month/Day/Year)								Line)	6. Individual or Joint/Group Filing (Check Applicable X Form filed by One Reporting Person Form filed by More than One Reporting
(City)		(State)	(Zip)												Person
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)						Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 2A. Deemed 3. 4. Securities Acquired (A) or Execution Date, Transaction Disposed Of (D) (Instr. 3, 4 and if any Code (Instr. 5) (Month/Day/Year) 8)					5. Amount of Securities Beneficially Owned Following (I) (Instr. 4) Reported		6. Ownership Form: Direct (D) or Indirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)
						(A) or Code V Amount (D)					Price	Transaction(s) (Instr. 3 and 4)
			Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned								(e.g., puts, calls, warrants, options, convertible securities)
1. Title of 2. 3. Transaction 3A. Deemed 4. Derivative Conversion Date Execution Date, Security or Exercise (Month/Day/Year) if any (Instr. 3) Price of (Month/Day/Year) 8) Derivative Security				Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and 7. Title and Amount Expiration Date of Securities (Month/Day/Year) Underlying Derivative Security (Instr. 3 and 4)					8. Price of 9. Number of Derivative derivative Security Securities (Instr. 5) Beneficially Owned Following Reported Transaction(s) (Instr. 4)			10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
														Amount or Number

Date Exercisable

(1) 50,000 (1) 02/03/2031 Common

Expiration Date Title

Explanation of Responses:

Stock Option (right to buy)

1. The Stock Option will vest in 4 equal installments as follows: 12,500 shall vest on each of December 31, 2021, December 31, 2022, December 31, 2023 and December 31, 2024.

Code V (A) (D)

/s/ Joshua Hexter 02/08/2021

Stock 50,000 \$⁰ 50,000 ^D

** Signature of Reporting Person Date

of Shares

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\$10.4 02/03/2021 A

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Instruction 1(b).

FORM	4
------	---

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

								or Section 30(h) of the Investment Company Act of 1940
1. Name and Address of Reporting Person* Gabay Avraham						2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. [ ORMP ]							(Check all applicable) Director X	Officer (give title	5. Relationship of Reporting Person(s) to Issuer 10% Owner Other (specify
(Last) (First) (Middle) MAMILLA 20, JERUSALEM						3. Date of Earliest Transaction (Month/Day/Year) 02/03/2021							below) below) CFO, Treasurer and Secretary
(Street) JERUSALEM L3 9414904 (City) (State) (Zip)								4. If Amendment, Date of Original Filed (Month/Day/Year)				Line)	X Person		6. Individual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting
			Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) Date				2. Transaction (Month/Day/Year)	2A. Deemed 3. 4. Securities Acquired (A) or Execution Date, Transaction Disposed Of (D) (Instr. 3, 4 and if any Code (Instr. 5) (Month/Day/Year) 8)					5. Amount of Securities Beneficially Reported	Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
					(A) or Code V Amount (D)						Price	Transaction(s) (Instr. 3 and 4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			of Securities Underlying Derivative Security (Instr. 3 and 4)	7. Title and Amount	8. Price of 9. Number of Derivative derivative Security Securities (Instr. 5) Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code V		(A)	(D)	Date Exercisable		Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$10.4	02/03/2021		(1) A		40,000		(1)			02/03/2031 Common Stock	40,000	\$0	40,000	D

Explanation of Responses:

1. The Stock Option will vest in 4 equal installments as follows: 10,000 shall vest on each of December 31, 2021, December 31, 2022, December 31, 2023 and December 31, 2024.

/s/ Avraham Gabay	02/08/2021
-------------------	------------

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.